Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The efficacy of magnesium oxide and sodium valproate in prevention of migraine headache: a randomized, controlled, double-blind, crossover study

The efficacy of magnesium oxide and sodium valproate in prevention of migraine headache: a... Migraine is a disabling disorder that affects the quality of life of patients. Different medications have been used in prevention of migraine headache. In this study, we evaluated the effectiveness of magnesium oxide in comparison with valproate sodium in preventing migraine headache attacks. This is a single-center, randomized, controlled, crossover trial which is double-blind, 24-week, 2-sequence, 2-period, 2-treatment. After patient randomization into two sequences, the intervention group received magnesium oxide 500 mg and the control group received valproate sodium 400 mg two tablets each day (every 12 h) for 8 weeks. The primary efficacy variable was reduction in the number of migraine attacks and number of days with moderate or severe headache and hours with headache (duration) per month in the final of 8 weeks in comparison with baseline. Seventy patients were randomized and seven dropped out, leaving 63 for analysis. In an intention-to-treat analysis, 31 patients were in group 1 (magnesium oxide–valproate) and 32 patients were in group 2 (valproate–magnesium oxide). The mean number of migraine attacks and days per month was 1.72 ± 1.18 and 2.09 ± 1.70, with a mean duration of 15.50 ± 21.80 h in magnesium group and 1.27 ± 1.27 and 2.22 ± 1.96, with a mean duration 13.38 ± 14.10 in valproate group. This study has shown that 500 mg magnesium oxide appears to be effective in migraine prophylaxis similar to valproate sodium without significant adverse effect. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Acta Neurologica Belgica Springer Journals

The efficacy of magnesium oxide and sodium valproate in prevention of migraine headache: a randomized, controlled, double-blind, crossover study

Download PDF
7 pages

Loading next page...
 
/lp/springer-journals/the-efficacy-of-magnesium-oxide-and-sodium-valproate-in-prevention-of-8Ws44pz0Qo
Publisher
Springer Journals
Copyright
Copyright © Belgian Neurological Society 2019
Subject
Biomedicine; Neurosciences; Neurology; Neuroradiology; Medicine/Public Health, general
ISSN
0300-9009
eISSN
2240-2993
DOI
10.1007/s13760-019-01101-x
Publisher site
See Article on Publisher Site

Abstract

Migraine is a disabling disorder that affects the quality of life of patients. Different medications have been used in prevention of migraine headache. In this study, we evaluated the effectiveness of magnesium oxide in comparison with valproate sodium in preventing migraine headache attacks. This is a single-center, randomized, controlled, crossover trial which is double-blind, 24-week, 2-sequence, 2-period, 2-treatment. After patient randomization into two sequences, the intervention group received magnesium oxide 500 mg and the control group received valproate sodium 400 mg two tablets each day (every 12 h) for 8 weeks. The primary efficacy variable was reduction in the number of migraine attacks and number of days with moderate or severe headache and hours with headache (duration) per month in the final of 8 weeks in comparison with baseline. Seventy patients were randomized and seven dropped out, leaving 63 for analysis. In an intention-to-treat analysis, 31 patients were in group 1 (magnesium oxide–valproate) and 32 patients were in group 2 (valproate–magnesium oxide). The mean number of migraine attacks and days per month was 1.72 ± 1.18 and 2.09 ± 1.70, with a mean duration of 15.50 ± 21.80 h in magnesium group and 1.27 ± 1.27 and 2.22 ± 1.96, with a mean duration 13.38 ± 14.10 in valproate group. This study has shown that 500 mg magnesium oxide appears to be effective in migraine prophylaxis similar to valproate sodium without significant adverse effect.

Journal

Acta Neurologica Belgica – Springer Journals

Published: Feb 23, 2019

References

  • Towards a rational understanding of migraine trigger factors
    Martin, VT; Behbehani, MM
  • Migraine headache disability and health-related quality-of-life: a population-based case-control study from England
    Lipton, RB; Liberman, JN; Kolodner, KB; igal, ME; Dowson, A; Stewart, WF
  • Migraine prevalence. A review of population-based studies
    Stewart, WF; Shechter, A; Rasmussen, BK
  • Epidemiology of headaches in Tehran urban area: a population based cross-sectional study in district 8, year 2010
    Shahbeigi, S; Fereshtehnejad, SM; Mohammadi, N
  • Comparison of the effect of topiramate and sodium valporate in migraine prevention: a randomized blinded crossover study
    Shaygannejad, V; Janghorbani, M; Ghorbani, A; Ashtary, F; Zakizade, N; Nasr, V
  • Single-dose intravenous sodium valproate (Depakine) versus dexamethasone for the treatment of acute migraine headache: a doubleblind randomized clinical trial
    Karimi, N; Tavakoli, M; Yazdani Charati, J; Shamsizade, M
  • The role of magnesium in migraine pathogenesis. Potential use of magnesium compounds in prevention and treatment of migraine headaches
    Rybicka, M; Baranowska-Bosiacka, I; Żyluk, B; Nowacki, P; Chlubek, D
  • Mitochondria, magnesium and migraine
    Welch, KM; Ramadan, NM
  • Blood magnesium levels in migraine
    Schoenen, J; Sianard -Gainko, J; Lenaerts, M
  • Magnesium prophylaxis of menstrual migraine: effects on intracellular magnesium
    Facchinetti, F; Sances, G; Borella, P; Genazzani, AR; Nappi, G
  • Hyperreactivity of platelets from spontaneously hypertensive rats. Role of external magnesium
    Baudouin-Legros, M; Dard, B; Guichency, P
  • Withdrawal of magnesium causes vasospasm while elevated magnesium produced relaxation of tone in cerebral arteries
    Altura, BT; Altura, BM
  • Pathobiology of magnesium deficiency: a cytokine/neurogenic inflammation hypothesis
    Weglicki, WB; Phillips, TM
  • The use of intravenous magnesium sulphate for acute migraine: meta-analysis of randomized controlled trials
    Choi, H; Parmar, N
  • Prophylaxis of migraine with oral magnesium: results from a prospective, multicenter, placebo-controlled and double-blind randomized study
    Peikert, A; Wilimzig, C; Köhne-Volland, F
  • Magnesium in the prophylaxis of migraine—a double-blind, placebo-controlled study
    Pfaffenrath, V; Wessely, P; Meyer, C; Isler, HR; Evers, S; Grotemeyer, KH; Taner, Z; Soycal, D; G’bell, H; Fischer, M
  • The effects of magnesium prophylaxis in migraine without aura
    Koseoglu, E; Talashoglu, A; Gonul, AS; Kula, M
  • A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: a randomized trial
    Maizels, M; Blumenfeld, A; Burchette, R
  • Flunarizine combined with magnesium polarization liquid on treating refractory migraine
    Zhou, Y; Gao, L
  • Observation of clinical effects of magnesium valproate combined with venlafaxine HCl in 54 individuals with migraine
    Hu, CS; Zhou, LB
  • Clinical observation om potassium magnesium asparate oral soluation combined with flinarizine capsule for migraine prophylaxis
    Bian, X; Zhu, Y; Xia, J; Ai, HJ; Guo, QY; Lu, LB; Zhang, QW
  • Observation of effects of nimodipine and magnesium sulfate combination for treating migraine
    Tang, XY; Lin, WZ; Zheng, XM; Liu, CS
  • The efficacy of different oral magnesium supplements for migraine prevention: a literature review
    Alghadeer, SM
  • Effects of intravenous and oral magnesium on reducing migraine: a meta-analysis of randomized controlled trials
    Chiu, HY; Yeh, TH; Huang, YC; Chen, PY
  • Canadian Headache Society guideline for migraine prophylaxis
    Pringsheim, T; Davenport, W; Mackie, G
  • An evidence-based review of oral magnesium supplementation in the preventive treatment of migraine
    Teigen, L; Boes, ChJ
  • Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo
    Hering, R; Kuritzky, A
  • Guidelines for controlled trials of drugs in migraine. Third edition. A guide for investigators
  • The international classification of headache disorders, 3rdedn (beta version)
  • A study of the feasibility of Internet administration of a computerized health survey: the headache impact test (HIT)
    Bayliss, MS; Dewey, JE; Dunlap, I; Batenhorst, AS; Cady, R; Diamond, ML; Sheftell, F
  • Migraine disability assessment (MIDAS) score: relation to headache frequency, pain intensity, and headache symptoms
    Stewart, WF; Lipton, RB; Kolodner, K
  • Comparison of validity and reliability of the migraine disability assessment (MIDAS) versus headache impact test (HIT) in an Iranian population
    Ghorbani, A; Chitsaz, A
  • Oral magnesium oxide prophylaxis of frequent migrainous headache in children: a randomized, double-blind, placebo-controlled trial
    Wang, F; Eeden, SK; Ackerson, LM; Salk, SE; Reince, RH; Elin, RJ
  • The effects of magnesium, l-carnitine, and concurrent magnesium-l-carnitine supplementation in migraine prophylaxis
    Tarighat Esfanjani, A; Mahdavi, R; Ebrahimi Mameghani, M; Talebi, M; Nikniaz, Z; Safaiyan, A
  • Improvement of migraine symptoms with a proprietary supplement containing riboflavin, magnesium and Q10: a randomized, placebo-controlled, double-blind, multicenter trial
    Gaul, C; Diener, H-C; Danesch, U
  • A comparative study of magnesium, flunarizine and amitriptyline in the prophylaxis of migraine
    Demirkaya, S; Dora, B; Topcuoglu, MA; Vural, O; U, HU
  • Serum ionized magnesium levels and serum ionized calcium/ionized magnesium ratios in women with menstrual migraine
    Mauskop, A; Altura, BT; Altura, BM
  • Serum and red cell magnesium levels in patients with premenstrual tension
    Abraham, GE; Lubran, MM